PDF-Guided PCI vs. CABG

FAME 3 Trial FFR William F Fearon MD Associate Professor of Medicine Director Interventional Cardiology Stanford University Medical Center Background SYNTAX Trial One Year MACCE Results Ser. CPORT- E Trial. Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals . with and without on-site cardiac surgery. Motivation for Trial. Sustain primary PCI program at no-SOS hospitals. Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators. Committees and . D. isclosures. Academic Executive Committee. E. Magnus Ohman, MB - Co-chair. C. Michael Gibson, MS, MD - Co-chair. Matthew T. Roe, MD, MHS. Sawan. , Bassam . Abou. Khalil.. Faculty of Medicine, University of . Balamand. , Beirut, Lebanon.. Daniel J. Rader.. Perelman School of Medicine, University of Pennsylvania, PA USA.. Very Severe Hypertriglyceridemia Prior to CABG: . Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators. Committees and . D. isclosures. Academic Executive Committee. E. Magnus Ohman, MB - Co-chair. C. Michael Gibson, MS, MD - Co-chair. Matthew T. Roe, MD, MHS.  . In . the SYNTAX Trial (1800 patients with 3-vessel or left main CAD randomized to CABG or PCI (in a 1:1 ratio), rates of . MACCE at . 12 months were significantly higher in the PCI group (17.8%, vs. 12.4%, P = 0.002. Revascularization in Stable Ischemic Heart Disease. Bobby Mathew, MD. LSU Internal Medicine, HO-II. Definitions. Recommendations for revascularization in the setting of symptomatic, stable ischemic heart disease; does not include revascularization in the setting of acute MI. Results from the FAME 2 trial. William . Fearon. , Bernard De . Bruyne. , . Nico. . Pijls. , David . Shilane. , Derek . Boothroyd. , . Pim. . Tonino. , . Emmanuele. . Barbato. , Peter . Juni. vascular disease renaldisease CRI is an independent risk factor hepatic insufficiency will change anestheticmanagementAllergiesMedications Look specifically for anti-anginal regimen - synergism betwe vs.. . c. oronary artery bypass for multi-vessel disease: a meta-analysis. . Nirav C Patel MD, Jonathan M Hemli MD, Karthik Seetharam MD, Annapoorna Uttara BS, Derek R Brinster MD,. . Luigi Pirelli MD, Chad . moderator:. Jeremy Rock. President ● . RockIT. Group. Agenda. PCI Overview. Removing Card Data From Your Hotel. . Best Practices. Questions & Answers. PCI. . Overview. Presenters:. Mark Haley, . Bo Xu, . Shengxian. Tu, Lei Song, . Zening. . Jin. , Bo Yu, . Guosheng. Fu, . Yujie. Zhou, . Jian’an. Wang, . Yundai. Chen, Jun Pu, . Lianglong. Chen, . Xinkai. Qu, . Junqing. Yang, . Xuebo. Intravascular Ultrasound . to Guide Percutaneous Coronary Intervention. . The FLAVOUR trial. Bon-Kwon Koo, MD, PhD. Seoul National University Hospital, Seoul, . Republic of Korea. Bon-Kwon Koo, MD, PhD. Joo-Yong Hahn. Samsung Medical Center, Seoul, Korea. FFR vs. Angiography-guided PCI in AMI with multivessel disease. Background. In patients with acute myocardial infarction (AMI) and multivessel coronary artery disease, percutaneous coronary intervention (PCI) of non-infarct related artery (IRA) lesions for complete revascularization improves clinical outcomes. . lesions. The hazard . was highest . with CABG in the first 30 . days with better outcomes with PCI; between . 30 days and . 5 . years, . outcomes were inferior . with PCI compared with . CABG. CABG. (n = 592).